Form 4: Avadel Pharmaceuticals Director Linda Palczuk Acquires Shares

Director Linda Palczuk of Avadel Pharmaceuticals PLC purchased 3,000 ordinary shares at a weighted average price of $10.1892.

Summary

• Linda Palczuk, a director at Avadel Pharmaceuticals PLC, acquired 3,000 ordinary shares on December 6, 2024.
• The shares were purchased at a weighted average price of $10.1892.
• The transactions occurred at prices ranging from $10.18 to $10.1899 per share.
• Following the transaction, Ms. Palczuk directly owns 66,400 ordinary shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive as it reflects a director's purchase of shares, which can be seen as a sign of confidence, but it is a routine transaction.

Positives

• The director's purchase of shares could be seen as a positive signal of confidence in the company's future.

Industry Context

This is a routine filing related to insider trading activity and is common for publicly traded companies.

Comparison to Industry Standards

• This type of filing is standard practice for directors and officers of publicly traded companies when they engage in transactions involving their company's stock.
• Similar filings are made by directors and officers of companies such as Teva Pharmaceuticals, Mylan, and Viatris when they buy or sell shares.

Stakeholder Impact

• The share purchase may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Avadel Pharmaceuticals, insider trading, share purchase, director, Linda Palczuk, ordinary shares